Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

Exclusion Criteria

• •1. Prior history of MI / PCI / coronary artery bypass graft (CABG) within previous 1 year
• •2. Patients with previous history of left ventricular ejection fraction (LVEF) \< 40%
• •3. Use of investigational drugs or devices 30 days prior to randomization
• •4. Known allergy or contra-indication to gadolinium/contrast agents
• •5. eGFR \< 30 ml/kg/min
• •6. Any contraindication against cardiac MRI (such as metal implants)
• •7. Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative pregnancy test prior to randomization
• •8. Body weight \> 140 kg (or 309 lbs.)
• •9. Absolute neutrophil count - ANC \< 1.5 k/cumm
• •10. History of Chronic Liver Disease
• •11. Elevated hepatic enzymes (BOTH ALT and AST) \> 2 times of upper normal limit
• •12. Patients with iron storage disease (hemochromatosis, thalassemia) or who are already treated with iron chelators
• •13. Any clinically significant abnormality identified prior to randomization that in the judgment of the Sponsor-Investigator or Delegate would preclude safe completion of the study or confound the anticipated benefit of deferiprone.
• •14. Life expectancy of less than 1 year due to non-cardiac pathology